BMS Reports the EC’s Approval of Breyanzi to Treat R/R Follicular Lymphoma
Shots:
- The EC has approved Breyanzi for r/r follicular lymphoma adults treated with ≥2 previous lines of systemic therapy in 30 EEA states
- Approval was based on global P-II (TRANSCEND FL) study, assessing Breyanzi’s safety & efficacy to treat r/r indolent B-cell NHL incl. FL
- In pts treated in 3L+ setting, study met its 1EP with an ORR of 97.1%, while also achieving its 2EP of 94.2% CR rate. Subsequently, it showed mToR of 0.95mos., with 75.7% pts maintaining response at 18mos.
Ref: BMS | Image: BMS
Related News:- BMS’ Opdivo Qvantig SC Injection Secures the US FDA’s Approval for Solid Tumor Opdivo Indications
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
